FDA denies a petition to exempt certain radiology AI software from 510(k) review, stressing ongoing regulatory oversight.
Key Details
- 1FDA rejected Harrison.ai's petition seeking 510(k) exemption for four types of radiology AI (CADx, CADe, CADt, CADe/x) under specific classifications.
- 2At least 255 radiology AI devices received 510(k) clearance in 2025 alone, per FDA records.
- 3FDA clarified prior clearance does not guarantee manufacturer competence for future device development.
- 4Manufacturer-proposed self-evaluation and risk plans were dismissed due to insufficient FDA oversight mechanisms.
- 5Most public comments opposed the exemption, and FDA detailed significant differences between CADe, CADx, and CADe/x devices impacting regulatory needs.
- 6The agency emphasized vulnerabilities in relying on end-users (radiologists) to catch all performance issues.
Why It Matters
This decision underscores the FDA’s commitment to robust regulatory oversight for radiology AI, potentially affecting product development timelines and market strategies. The nuanced treatment of different device categories and the rejection of broad user detection arguments highlight stringent evidentiary requirements that developers must meet.
Source
AuntMinnie
Related News
•AuntMinnie
AI in Radiology: Augmentation, Not Replacement – Risks and Realities Reviewed
AI is reshaping radiology workflows but is not ready to replace radiologists, as judgment, accountability, and clinical complexity remain unmet by current technology.
•AuntMinnie
AI-CAD Boosts Specificity and Efficiency in Asia-Pacific Mammography Study
AI-CAD systems increased specificity and cut interpretation times in a multicenter Asia-Pacific mammography study.
•AuntMinnie
AI-Driven Mammogram Analysis Boosts Cardiovascular Risk Prediction in Women
AI quantification of breast arterial calcifications (BACs) on mammograms enhances prediction of cardiovascular events beyond traditional risk models.